ClinicalTrials.Veeva

Find clinical trials for Acute Myeloid Leukemia (AML) in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Cleveland, OH, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

Cleveland, Ohio, United States and 125 other locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Cleveland, Ohio, United States and 164 other locations

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Cleveland, Ohio, United States and 23 other locations

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Pevonedistat

Phase 2

Takeda
Takeda

Cleveland, Ohio, United States and 56 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE)

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Cleveland, Ohio, United States and 33 other locations

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...

Enrolling
AML With Monocytic Differentiation
CMML
Biological: IO-202 and Azacitidine
Biological: IO-202

Phase 1

Immune-Onc Therapeutics

Cleveland, Ohio, United States and 13 other locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Cleveland, Ohio, United States and 222 other locations

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Cleveland, Ohio, United States and 43 other locations

Locations recently updated

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human ...

Enrolling
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Biological: VOR33
Drug: Mylotarg

Phase 1, Phase 2

Vor Biopharma

Cleveland, Ohio, United States and 10 other locations

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant (ARTEMIS)

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML...

Active, not recruiting
Acute Myeloid Leukemia
Stem Cell Transplantation
Drug: MT-401

Phase 2

Marker Therapeutics

Cleveland, Ohio, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems